Roche and Reverie Labs Collaborate to Advance Kinase Drug Discovery Programs

Shots:

• Reverie Labs to receive up front and is eligible to receive pre/clinical, regulatory milestones, as well as royalties on Roche’s sales of drug candidates, emerges from the collaboration
• Reverie Labs will deploy its technology platform to perform virtual screening, hit-to-lead generation, and lead optimization on kinase inhibitor discovery programs, alongside scientists at Roche and Genentech
• Reverie Labs uses its highly scalable infrastructure to train ML models for kinase potency, kinome selectivity, and ADMET properties for generating millions of novel chemical structures to evaluate the ideal combination of properties

Click here to read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology